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mechanisms of resistance to targeted therapies in cancer. Non-small-
cell lung cancer (NSCLC) is still an untreatable disease and is the leading
cause of cancer related deaths worldwide (Gridelli et al., 2015). Various
strategies have been proposed to increase the survival of NSCLC pa-
tients, including early diagnosis (Gridelli et al., 2015). Indeed, 5-year
survival rates can reach 70% with surgical resection in stage IA disease.
No beneﬁt has been shown for adjuvant chemotherapy in stage IA.
However,most patients are diagnosed at later stages (at initial diagnosis
55% of patients have metastatic disease) (Gridelli et al., 2015). NSCLC
gene signatures have uncovered typical protein-coding gene mutations
aswell as subsets ofmicroRNAs (miRNAs) that are aberrantly expressed
(Rosell & Karachaliou, 2015). The main challenge faced by physicians
doing CT screening for lung cancer is that about half of the individuals
screened have one ormore pulmonary nodules, but only a small percent
of these individuals have lung cancer (Gridelli et al., 2015). In the Mul-
ticenter Italian Lung Detection (MILD) trial the plasmamiRNA signature
was predictive of malignancy risk and was able to distinguish lung
cancers from the majority of benign pulmonary nodules detected by
low-dose CT (Sozzi et al., 2014). Interestingly, two tumor-suppressive
miRNAs, let-7 and miR-34, are the most common altered miRNAs in
NSCLC tumor tissue The reduction in let-7 andmiR-34 expression is rel-
evant in the NSCLC oncogenic phenotype and is involved in the mainte-
nance of oncogene addiction, via RAS, BCL2, MET or MYC. Systemic
nanodelivery ofmiR-34 and let-7 suppresses tumor growth. This combi-
natorial miRNA approach engages numerous components of tumor cell-
addictive pathways and could eventually result in a novel therapeutic
approach (Kasinski et al., 2015). Small nodules (those with a volume
b100 mm (Sozzi et al., 2014) or a diameter b5 mm) are not predictive
for lung cancer. Immediate diagnosis evaluation is warranted for large
nodules (N300 mm (Sozzi et al., 2014) or a diameter N10 mm). Based
on the NELSON trial, volume doubling time assessment is also recom-
mended for intermediate size nodules (Horeweg et al., 2014). InDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.001.
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lung tumors do not present lymph node metastases or recur with met-
astatic disease. This is likely due to the inability of cells to disseminate,
however, unfortunately, even patients who have potentially curative
surgery often relapse to the presence of metastasis below detection
level at the time of diagnosis. Molecular mediators of NSCLC metastasis
have been reported by Hu et al. who deﬁned gene signatures that strat-
ify the recurrence-free-survival (Hu et al., 2015). The authors of the
MILD study (Sozzi et al., 2014) have now identiﬁed through a multi-
gene signature that tumors identiﬁed by CT screening can be distin-
guished between indolent and aggressive tumors, with different free-
recurrence survivals at 5 years in stage I NSCLC patients. Their results
also point out that more virulent tumors are those identiﬁed in the
later years of follow-up and the gene signature indicates a hyper-
activation of the PI3K–PTEN–AKT pathway with up-regulation of
ITGB1 and inhibition of FOXO1A expression (Hu et al., 2015). The phos-
phatidylinositol 3-kinase (PI3K) is a universal tumor driver that
integrates growth factor signaling with downstream circuitries of cell
proliferation. Hu et al. have found that developing lung cancer between
3 and 5 years of CT screening more frequently involves increased gene
expression of β Integrins (ITGB1), as shown in Fig. 5, where ITGB1 di-
rectly interacts with Integrin-linked kinase (ILK) and phosphorylates
AKT in a PI3K-dependent manner (Hu et al., 2015). NSCLC is frequently
associated with epidermal growth factor receptor (EGFR) over expres-
sion, gene ampliﬁcation and acquired gain of function mutations.
EGFR signaling in NSCLC promotes tumor growth, survival andmetasta-
sis (Gridelli et al., 2015). EGFR and other growth factors activate the
crosstalk between signaling pathways (Rosell et al., 2013), including
ILK/AKT, extracellular signal regulated kinase ½ (ERK1/2), signal trans-
ducers and activators of transcription 3 (STAT3) and NOTCH1 andHES1.
Blockade of PI3K or ILK signalingwith selective compounds could inhib-
it the phosphorylation of AKT and glycogen synthase kinase 3β, sup-
press STAT3 and ERK1/2 activation and also decrease NOTCH1 and
HES1 expression. Hypoxia is responsible for activating ILK–AKT–Y
box-binding protein 1 (YB-1), leading to the inhibition of FOXO3A and
activation of epithelial–mesenchymal transition markers (ZEB1, Twist)
and expression of biomarkers associatedwith cancer stem cell signaling
pathways (Chou et al., 2015). Fig. 5 (Hu et al., 2015) epitomizes the
crosstalk between signaling pathways that could be traced withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
783R. Rosell et al. / EBioMedicine 2 (2015) 782–783biomarkers in future studies and could serve as theranostic markers for
deﬁning the free recurrence interval and adequate targeted therapy. A
major caveat is that single targeted therapy can promote tumor adapta-
tion and paradoxically promote tumor invasion and metastases
(Arasada et al., 2014). In summary, Hu et al. (2015) highlight the need
for PCR array analysis of important components of signaling pathways
that could provide prompt answers on tumor behavior and serve to cus-
tomize combinatorial therapies.
Acknowledgments
Work in RR's laboratory is supported by a grant from La Caixa
Foundation and by a grant from Redes Tematicas de Investigación en
Cáncer (RD12/0036/0072).
References
Arasada, R.R., Amann, J.M., Rahman, M.A., Huppert, S.S., Carbone, D.P., 2014. EGFR blockade
enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer
Res. 74, 5572–5584.Chou, C.C., Chuang, H.C., Salunke, S.B., Kulp, S.K., Chen, C.S., 2015. A novel HIF-1alpha-
integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1alpha
expression and epithelial–mesenchymal transition in cancer cells. Oncotarget 6,
8271–8285.
Gridelli, C., Rossi, A., Carbone, D.P., et al., 2015. Non-small-cell lung cancer. Nature
Reviews Disease Primersp. 15009.
Horeweg, N., van Rosmalen, J., Heuvelmans, M.A., et al., 2014. Lung cancer probability in
patients with CT-detected pulmonary nodules: a prespeciﬁed analysis of data from
the NELSON trial of low-dose CT screening. Lancet Oncol. 15, 1332–1341.
Hu, J., Boeri, M., Sozzi, G., et al., 2015. Gene signatures stratify computed tomography
screening detected lung cancer in high-risk populations. EBioMedicine http://dx.
doi.org/10.1016/j.ebiom.2015.07.001 (http://www.sciencedirect.com/science/
article/pii/S235239641530058X).
Kasinski, A.L., Kelnar, K., Stahlhut, C., et al., 2015. A combinatorial microRNA therapeutics
approach to suppressing non-small cell lung cancer. Oncogene 34, 3547–3555.
Rosell, R., Karachaliou, N., 2015. Relationship between gene mutation and lung cancer
metastasis. Cancer Metastasis Rev. (Epub ahead of print).
Rosell, R., Bivona, T.G., Karachaliou, N., 2013. Genetics and biomarkers in personalisation
of lung cancer treatment. Lancet 382, 720–731.
Sozzi, G., Boeri, M., Rossi, M., et al., 2014. Clinical utility of a plasma-based miRNA signature
classiﬁer within computed tomography lung cancer screening: a correlative MILD trial
study. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol. 32, 768–773.
